NCT03800524进行中（未招募）3 期
Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 337
- 试验地点
- 25
- 主要终点
- Number of responder patients
研究概览
简要总结
This is a Phase III, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS).
详细描述
Enrolled patients will be randomized to one of two treatment arms: TUDCA or identical placebo by oral route. The randomization will be performed in a ratio one to one for the two arms.
TUDCA will be administered orally at the dose of 1 g twice daily (2 g daily) for 18 months. Patients will be taking also riluzole at the dose of 50 mg twice daily (100 mg daily).
Patient randomization will take place after a screening (lead-in) period of 12 weeks (3 months) with 3 assessments at 6-week intervals. Clinical assessments during the trial phase will be performed every three months. This will allow measuring the progression rate before and after starting treatment (either active or placebo).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Probable laboratory-supported, probable, or definite ALS, as defined by El Escorial Revised ALS diagnostic criteria at screening visit (month -3)
- •Disease duration ≤ 18 months at screening visit (month -3)
- •Able to perform reproducible pulmonary function tests at screening visit (month -3)
- •Forced vital capacity or slow vital capacity ≥70% of normal at screening visit (month -3)
- •Stable on riluzole treatment for 3 months in the lead-in period
- •Signed informed consent at screening visit (month -3)
排除标准
- •Treatment with edaravone
- •Other causes of neuromuscular weakness
- •Presence of other neurodegenerative diseases
- •Significant cognitive impairment, clinical dementia or psychiatric illness
- •Severe cardiac or pulmonary disease
- •Other diseases precluding functional assessments
- •Other life-threatening diseases
- •Any use of non-invasive ventilation (e.g. continuous positive airway pressure, non-invasive bi-level positive airway pressure or non-invasive volume ventilation) for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation
- •Gastrointestinal disorder that is likely to impair absorption of study drug from the gastrointestinal tract
- •Has taken any investigational study drug within 30 days or five half-lives of the prior agent, whichever is longer, prior to dosing
- •Any clinically significant laboratory abnormality
- •Other concurrent investigational medications
- •Active peptic ulcer
- •Previous surgery or infections of small intestine
- •Patients unable to easily swallow the treatment pills
- •Acute inflammation of the gallbladder or bile ducts
- •Occurrence of frequent biliary colic, biliary infections, severe pancreatic abnormalities
- •Bile duct obstruction, calcified X-ray opaque gallstones and reduced mobility of the gallbladder
- •Subjects who weigh 88 lbs (40 kg) or less
- •Aspartate aminotransferase or alanine aminotransferase concentrations more than 3 times the upper limit of normal
- •Creatinine clearance 50 ml/min or less
- •Any clinically significant neurological, haematological, autoimmune, endocrine, cardiovascular, neoplastic, renal, gastrointestinal, or other disorder that, in the Investigator's opinion, could interfere with the subject's participation in the study, place the subject at increased risk, or confound interpretation of study results
- •Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive TUDCA or that the subject is unable or unlikely to comply with the dosing schedule or study evaluations
- •The patient of reproductive potential is sexually active and is not willing to use highly effective contraception during the study and up to 90 days after the day of last dose
- •The patient is pregnant or breast feeding
研究组 & 干预措施
Tauroursodeoxycholic acid (TUDCA)
Experimental
- Tauroursodeoxycholic acid (TUDCA) 250 mg capsules
- Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal
- Mode of administration: orally
- Duration: 18 months
干预措施: Tauroursodeoxycholic Acid (Drug)
Reference therapy
Placebo Comparator
- Placebo capsules identical to active compound
- Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal
- Mode of administration: orally
- Duration: 18 months
干预措施: Placebo (Drug)
结局指标
主要结局
Number of responder patients
时间窗: 18 months
Identification of the responder patients defined as those showing an improvement of at least 20% in the ALSFRS-R slope
次要结局
- Medical Research Council (MRC) scale(18 months)
- Neurofilaments levels(18 months)
- Survival time(18 months)
- ALS disease functional rating scale - revised version (ALSFRS-R)(18 months)
- ALS Assessment Questionnaire-40 (ALSAQ-40)(18 months)
- Forced Vital Capacity(18 months)
- MMP-9 levels(18 months)
- EuroQol 5-Dimension-5 Levels (EQ-5D-5L) scale(18 months)
- Long-term safety and tolerability(18 months)
研究者
研究点 (25)
Loading locations...
相似试验
已完成
1 期
TUDCA as a Therapy for Ulcerative Colitis (UC)Ulcerative ColitisNCT04114292Washington University School of Medicine14
已完成
2 期
Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisNCT00877604Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta34
进行中（未招募）
1 期
Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-ontreatment in patients affected by amyotrophic lateral sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-002722-22-BEHumanitas Mirasole SpA320
招募中
3 期
Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)ALS10029317NL-OMON55527Humanitas Mirasole SpA20
进行中（未招募）
1 期
Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)amyotrophic lateral sclerosis (ALS)MedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-002722-22-ITIRCCS ISTITUTO CLINICO HUMANITAS440